Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
Healthtrust
US Department of Justice
Farmers Insurance
Medtronic
Citi
Teva
Covington
Julphar

Generated: August 18, 2017

DrugPatentWatch Database Preview

COLAZAL Drug Profile

« Back to Dashboard

Which patents cover Colazal, and what generic Colazal alternatives are available?

Colazal is a drug marketed by Valeant Pharms Intl and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-four patent family members in eleven countries.

The generic ingredient in COLAZAL is balsalazide disodium. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the balsalazide disodium profile page.

Summary for Tradename: COLAZAL

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list42
Clinical Trials: see list4
Patent Applications: see list2,143
Drug Prices:see details
DailyMed Link:COLAZAL at DailyMed

Pharmacology for Tradename: COLAZAL

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl
COLAZAL
balsalazide disodium
CAPSULE;ORAL020610-001Jul 18, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
Valeant Pharms Intl
COLAZAL
balsalazide disodium
CAPSULE;ORAL020610-001Jul 18, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: COLAZAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Intl
COLAZAL
balsalazide disodium
CAPSULE;ORAL020610-001Jul 18, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: COLAZAL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,921,344Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
9,192,616Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: COLAZAL

Country Document Number Estimated Expiration
Japan2013032395► Subscribe
China101610670► Subscribe
Japan2009506067► Subscribe
Mexico2009004826► Subscribe
Israel198513► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Chinese Patent Office
Baxter
Queensland Health
Federal Trade Commission
Covington
Medtronic
Johnson and Johnson
Daiichi Sankyo
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot